Global clinical trial CRO specializing in oncology and rare disease
Ergomed is a contract research organization managing clinical trials across oncology and rare disease, with 1,000+ employees spread across 13 countries. The hiring profile reveals a finance-heavy organization in transition: finance and research roles dominate the open pipeline, but the active project list—tax transfer pricing, ESG reporting, finance systems development, real-time dashboards—signals internal operational scaling rather than growth in core trial capacity. This suggests management bandwidth is split between regulatory/operational excellence and backend infrastructure modernization.
Notable leadership hires: Tax Director, Finance Director
Ergomed delivers end-to-end clinical trial management and pharmacovigilance services to pharmaceutical and biotech companies. The firm handles the full trial lifecycle from early phase through post-approval, with specialist focus on oncology and rare disease indications. Founded in 1997 and headquartered in Guildford, Surrey, the company operates a distributed model across the United States, Europe (UK, Ireland, Spain, Czechia, Romania, Bulgaria, Croatia, Serbia, Bosnia and Herzegovina), and South America (Argentina, Colombia). The service model covers regulatory compliance, trial operations, patient support, and data management for mid-to-large pharma clients.
Ergomed is a contract research organization (CRO) providing full-service clinical trial management, pharmacovigilance, and drug development support. Founded 1997, it specializes in oncology and rare disease trials for pharmaceutical and biotech companies.
Ergomed is headquartered in Guildford, Surrey, UK, and employs 1,001–5,000 people. It operates in 13 countries including the US, UK, Ireland, Spain, Czechia, Romania, Croatia, Serbia, Bosnia, Bulgaria, Argentina, and Colombia.
Other companies in the same industry, closest in size